Crinetics Pharmaceuticals (CRNX) Non-Current Deferred Tax Liability (2019 - 2024)

Crinetics Pharmaceuticals' Non-Current Deferred Tax Liability history runs 4 years deep, the most recent figure standing at $9.8 million for Q4 2024.

• In Q4 2024, Non-Current Deferred Tax Liability changed 0.49% year-over-year to $9.8 million; the TTM figure through Dec 2024 stood at $9.8 million (changed 0.49% YoY), while the FY2024 annual figure was $9.8 million, changed 0.49% from the prior year.
• Non-Current Deferred Tax Liability for Q4 2024 stood at $9.8 million, roughly flat from $9.8 million in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $9.8 million in Q4 2023, with the low at $453000.0 in Q4 2022.
• The 3-year median for Non-Current Deferred Tax Liability is $9.8 million (2024), against an average of $6.7 million.
• The sharpest annual moves came in 2023 and 2024: Non-Current Deferred Tax Liability surged 2063.13% in 2023, then slipped 0.49% in 2024.
• Crinetics Pharmaceuticals' Non-Current Deferred Tax Liability stood at $453000.0 in 2022, then soared by 2063.13% to $9.8 million in 2023, then slipped by 0.49% to $9.8 million in 2024.
• Business Quant data shows CRNX's Non-Current Deferred Tax Liability at $9.8 million in Q4 2024, $9.8 million in Q4 2023, and $453000.0 in Q4 2022.